Zacks Research Issues Optimistic Outlook for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities researchers at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a report issued on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.49 per share for the quarter, up from their previous forecast of $0.44. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.53 EPS, Q1 2026 earnings at $0.57 EPS, Q2 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.57 EPS.

A number of other research firms have also commented on CPRX. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $32.50.

Catalyst Pharmaceuticals Trading Up 2.5 %

CPRX opened at $23.16 on Friday. The stock’s 50 day simple moving average is $22.34 and its 200-day simple moving average is $21.58. The stock has a market cap of $2.81 billion, a PE ratio of 19.63, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a 1 year low of $14.47 and a 1 year high of $24.64.

Insiders Place Their Bets

In other news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after buying an additional 390,116 shares during the last quarter. Pacer Advisors Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after buying an additional 151,495 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Catalyst Pharmaceuticals by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock worth $56,477,000 after buying an additional 180,100 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $37,494,000. Finally, Bank of America Corp DE boosted its stake in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock worth $32,741,000 after buying an additional 913,843 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.